Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through equity or debt. The company is focused on growth through internal cash flows and CapEx investments, such as the Rs 123 crore Comfy plant expansion. No new large CapEx or funding requirements are foreseen beyond this. The company is cash-rich and debt-free, indicating no immediate need for external borrowing. Shareholder queries about buybacks and dividends were addressed, but no new equity issuance or debt raising plans were announced. Overall, the company appears to be prioritizing organic growth and efficient capital utilizati

Any current/future capex/capital investment/strategic investment?

The board approved a CapEx of Rs 123 crores for a new Comfy plant (announced in May). Business utilization rates are currently around 60%, so no major additional CapEx is foreseen beyond this. The Rs 123 crores CapEx for the Comfy plant is the large upcoming investment. The company aims to improve margins by expanding the growth of key brands—including Amrutanjan, Comfy, and ElectroPlus—expecting margin expansion by about 200 basis points. Projects are underway to cut freight costs, which are major cost drivers. Overall, CapEx focuses on capacity expansion (Comfy plant) and operational cost ef

Future growth expectations in sales/revenue/volumes?

The company is cautiously optimistic about growth returning to the core pain category, which showed degrowth post-COVID but is now growing at low double-digit rates. Sales growth in brands Amrutanjan, Comfy, and ElectroPlus is expected to drive margin expansion and overall revenue growth. The target is to achieve Rs 1000 crore turnover by 2028, viewed as an aspirational but achievable milestone. Distribution expansion is a key focus, especially adding 1 lakh new chemical shops in rural Maharashtra over 2-3 years to drive growth. None of the brands have reached peak revenue yet, indicating sign

Future growth expectations in earnings/operating earnings/profits/EPS?

Company aims for 15%-20% growth in sales and around 15% profit growth annually, reflecting in EPS increases as per shareholder aspirations (Page 19). EBIT margin target is to increase from 10.8% to 13% in the current financial year (Page 17). Margin expansion by approximately 200 basis points expected this year as Amrutanjan, Comfy, and ElectroPlus brands grow (Page 28). Focus on cost-cutting, especially freight, to improve margins, aiming for 13%-14% margins post-investments (Page 28). The target is to achieve Rs 1000 crores turnover by 2028, indicating substantial top-line and profit growth

Amrutanjan Health Care LtdQ1 FY25Pharmaceuticals & Biotechnology

Amrutanjan Health Care Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹496.65P/E: 23.1Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company is cautiously optimistic about growth returning to the core pain category, which showed degrowth post-COVID but is now growing at low double-digit rates.
Sales growth in brands Amrutanjan, Comfy, and ElectroPlus is expected to drive margin expansion and overall revenue growth.
The target is to achieve Rs 1000 crore turnover by 2028, viewed as an aspirational but achievable milestone.
Distribution expansion is a key focus, especially adding 1 lakh new chemical shops in rural Maharashtra over 2-3 years to drive growth.
None of the brands have reached peak revenue yet, indicating significant room for market penetration and volume growth.
Pricing strategies remain competitive with selective price increases aligned with inflation.
Investment in brand building, innovation, and operational efficiency (like cost-cutting freight expenses) aim to improve margins and sustain growth momentum.

Margin guidance

Category 1

Company aims for 15%-20% growth in sales and around 15% profit growth annually, reflecting in EPS increases as per shareholder aspirations (Page 19).
EBIT margin target is to increase from 10.8% to 13% in the current financial year (Page 17).
Margin expansion by approximately 200 basis points expected this year as Amrutanjan, Comfy, and ElectroPlus brands grow (Page 28).
Focus on cost-cutting, especially freight, to improve margins, aiming for 13%-14% margins post-investments (Page 28).
The target is to achieve Rs 1000 crores turnover by 2028, indicating substantial top-line and profit growth (Pages 7, 17, 27).
Company is cautiously optimistic with core pain category and overall sales growing post-pandemic dips (Page 27).
Continuous innovation, distribution expansion, and brand building to drive sustained earnings growth (Pages 27, 29).

See what Amrutanjan Health Care Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned fundraising through equity or debt.
The company is focused on growth through internal cash flows and CapEx investments, such as the Rs 123 crore Comfy plant expansion.
No new large CapEx or funding requirements are foreseen beyond this.
The company is cash-rich and debt-free, indicating no immediate need for external borrowing.
Shareholder queries about buybacks and dividends were addressed, but no new equity issuance or debt raising plans were announced.
Overall, the company appears to be prioritizing organic growth and efficient capital utilization over external fundraising.

Order book

The transcript from the 87th AGM does not explicitly mention details about the current or expected order book or pending orders for the company. The discussion primarily focuses on financial performance, market growth, product strategies, competition, distribution, green energy efforts, and future aspirations rather than specific order book status. - No direct information on current or expected order book provided. - Focus areas discussed: revenue growth targets, product distribution, market expansion. - Emphasis on brand growth (Amrutanjan, Comfy, ElectroPlus) and increasing market share. - Expansion plans include CapEx and new plant setup but no specific pending orders. - Customer experience, innovation, and competition addressed without order backlog details. Therefore, the transcript does not provide concrete data on order books or pending orders.

See what Amrutanjan Health Care Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The board approved a CapEx of Rs 123 crores for a new Comfy plant (announced in May).
Business utilization rates are currently around 60%, so no major additional CapEx is foreseen beyond this.
The Rs 123 crores CapEx for the Comfy plant is the large upcoming investment.
The company aims to improve margins by expanding the growth of key brands—including Amrutanjan, Comfy, and ElectroPlus—expecting margin expansion by about 200 basis points.
Projects are underway to cut freight costs, which are major cost drivers.
Overall, CapEx focuses on capacity expansion (Comfy plant) and operational cost efficiencies to support growth targets over the next 2-3 years.

Track Amrutanjan Health Care Ltd — get its next earnings analysis in your feed

How does Amrutanjan Health Care Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAmrutanjan Health Care Ltd

Rev 3Mar 1

See where Amrutanjan Health Care Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Amrutanjan Health Care Ltd rank in Pharmaceuticals & Biotechnology?

Compare Amrutanjan Health Care Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Amrutanjan Health Care Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →